MONTREAL, Feb. 11, 2019 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that its European subsidiary, Theratechnologies International Limited, has appointed Mr. Conor Walshe as its General Manager.
Mr. Walshe will be based in Dublin, Ireland, where Theratechnologies European head office will be established.
“We could not be happier with the hiring of Conor whom we will be able to rely on for his in-depth expertise, knowledge and acumen as we establish our presence in Europe. The potential launch of Trogarzo® in Europe requires the flawless implementation of an infrastructure that will be able to deliver on many key success factors including distribution, reimbursement, sales, marketing and relationships with key stakeholders,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.
“Conor was selected as General Manager, after a thorough European search, based on his demonstrated capacity and ability to deliver on those critical issues for Theratechnologies in Europe. As soon as he begins his mandate, he will be working with our contract sales organization on building the right field infrastructure in key European countries and he will complete the hiring of key internal strategic positions,” concluded Mr. Tanguay.
Prior to joining our European subsidiary, Mr. Walshe was General Manager and Vice President, Operations and Commercial, at Aralez Plc. Prior to Aralez Plc, Mr. Walshe spent more than 15 years in the pharmaceutical industry including at Perrigo Plc, Elan Plc and Venn Life Sciences where he was called upon to serve, among others, as CFO, Senior Vice President Commercial and Financial Operations and in product management.
Mr. Walshe is a Chartered Accountant. He holds a Bachelor of Commerce and a Master in Business Studies from the University College in Dublin. He also obtained a diploma in IFRS from the Institute of Chartered Accountants and in Advanced International Corporate Finance from INSEAD.
About Theratechnologies
Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company’s website at www.theratech.com and on SEDAR at www.sedar.com.
Forward-Looking Information
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements about the potential launch of Trogarzo® in Europe and the building of an infrastructure in relation to the potential commercialization of Trogarzo® in Europe.
Forward-looking statements are subject to a number of assumptions and are subject to a variety of risks and uncertainties, many of which are beyond our control that could cause our actual results to differ materially from those that are disclosed in or implied by the forward-looking statements contained in this press release. These assumptions include, but are not limited to, the following: Trogarzo® will be approved for commercialization in Europe, our infrastructure will allow us to successfully commercialize Trogarzo® in Europe, and Trogarzo® will be reimbursed by each country in which it will be commercially sold.
The risks and uncertainties referred to above include, but are not limited to, the following: Trogarzo® may not be approved for commercialization in Europe, and even if approved, its indication may contain limitation restricting its use, healthcare professionals and patients may not accept Trogarzo® and reimbursement coverage, if any, for Trogarzo® may differ from one country to the other.
We refer potential investors to the “Risk Factors” section of our annual information form dated February 6, 2018 for additional risks regarding the conduct of our business and Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.
We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.
For media inquiries:
Denis Boucher
Vice President, Communications and Corporate Affairs
514-336-7800